Titre :

Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management.

Auteur(s) :

Terpos, E. [Auteur]
National and Kapodistrian University of Athens [NKUA]
Branagan, A. R. [Auteur]
Massachusetts General Hospital [Boston]
García-Sanz, R. [Auteur]
Universidad de Salamanca [España] = University of Salamanca [Spain]
Trotman, J. [Auteur]
The University of Sydney
Greenberger, L. M. [Auteur]
Stephens, D. M. [Auteur]
University of Utah
Morel, Pierre [Auteur]
CHU Amiens-Picardie
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Kimby, E. [Auteur]
Karolinska Institutet [Stockholm]
Frustaci, A. M. [Auteur]
Hatjiharissi, E. [Auteur]
Hippokration General Hospital, Aristotle University Of Thessaloniki
San-Miguel, J. [Auteur]
Clínica Universidad de Navarra [Pamplona]
Dimopoulos, M. A. [Auteur]
National and Kapodistrian University of Athens [NKUA]
Treon, S. P. [Auteur]
Harvard Medical School [Boston] [HMS]
Dana-Farber Cancer Institute [Boston]
Leblond, V. [Auteur]
CHU Pitié-Salpêtrière [AP-HP]

Titre de la revue :

Seminars in Hematology

Nom court de la revue :

Semin Hematol

Date de publication :

2023-04-29

ISSN :

1532-8686

Mot(s)-clé(s) en anglais :

Waldenstrom's Macroglobulinemia
SARS-CoV-2
COVID-19
Vaccine
BNT162b2
mRNA-1273

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Consensus Panel 5 (CP5) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11; held in October 2022) was tasked with reviewing the current data on the coronavirus disease-2019 (COVID-19) prophylaxis ...
Lire la suite >Consensus Panel 5 (CP5) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11; held in October 2022) was tasked with reviewing the current data on the coronavirus disease-2019 (COVID-19) prophylaxis and management in patients with Waldenstrom's Macroglobulinemia (WM). The key recommendations from IWWM-11 CP5 included the following: Booster vaccines for SARS-CoV-2 should be recommended to all patients with WM. Variant-specific booster vaccines, such as the bivalent vaccine for the ancestral Wuhan strain and the Omicron BA.4.5 strain, are important as novel mutants emerge and become dominant in the community. A temporary interruption in Bruton's Tyrosine Kinase-inhibitor (BTKi) or chemoimmunotherapy before vaccination might be considered. Patients under treatment with rituximab or BTK-inhibitors have lower antibody responses against SARS-CoV-2; thus, they should continue to follow preventive measures, including mask wearing and avoiding crowded places. Patients with WM are candidates for preexposure prophylaxis, if available and relevant to the dominant SARS-CoV-2 strains in a specific area. Oral antivirals should be offered to all symptomatic WM patients with mild to moderate COVID-19 regardless of vaccination, disease status or treatment, as soon as possible after the positive test and within 5 days of COVID-19-related symptom onset. Coadministration of ibrutinib or venetoclax with ritonavir should be avoided. In these patients, remdesivir offers an effective alternative. Patients with asymptomatic or oligosymptomatic COVID-19 should not interrupt treatment with a BTK inhibitor. Infection prophylaxis is essential in patients with WM and include general preventive measures, prophylaxis with antivirals and vaccination against common pathogens including SARS-CoV-2, influenza, and S. pneumoniae.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2023-11-15T02:07:03Z
2024-04-08T08:07:34Z